Spero Therapeutics Analyst Ratings
Spero Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2023 | 305.41% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/10/2023 | 305.41% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 09/26/2022 | 305.41% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 09/23/2022 | 440.54% | Evercore ISI Group | $2 → $8 | Upgrades | In-Line → Outperform |
| 08/15/2022 | 372.97% | HC Wainwright & Co. | $10 → $7 | Maintains | Buy |
| 05/23/2022 | 575.68% | HC Wainwright & Co. | $37 → $10 | Maintains | Buy |
| 05/20/2022 | 35.14% | Berenberg | → $2 | Downgrades | Buy → Hold |
| 05/17/2022 | 237.84% | Cantor Fitzgerald | $27 → $5 | Maintains | Overweight |
| 05/04/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 05/04/2022 | 35.14% | Evercore ISI Group | $40 → $2 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 2400% | HC Wainwright & Co. | $43 → $37 | Maintains | Buy |
| 03/21/2022 | 2805.41% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 10/01/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 01/22/2021 | 2602.7% | HC Wainwright & Co. | $33 → $40 | Maintains | Buy |
| 12/16/2020 | 3075.68% | Berenberg | → $47 | Initiates Coverage On | → Buy |
| 11/23/2020 | 2129.73% | HC Wainwright & Co. | $28 → $33 | Maintains | Buy |
| 09/29/2020 | 4629.73% | Evercore ISI Group | → $70 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 1791.89% | HC Wainwright & Co. | $25 → $28 | Reiterates | → Buy |
| 03/17/2020 | 1318.92% | Stifel | $22 → $21 | Maintains | Buy |
| 11/05/2019 | 2264.86% | HC Wainwright & Co. | $28 → $35 | Maintains | Buy |
| 09/09/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 09/04/2019 | 1791.89% | HC Wainwright & Co. | → $28 | Assumes | → Buy |
| 10/16/2018 | 508.11% | B of A Securities | $19 → $9 | Downgrades | Neutral → Underperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/20/2023 | 305.41% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 2023 年 10 月 4 日 | 305.41% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 09/26/2022 | 305.41% | HC Wainwright & Co. | 7 美元 → 6 美元 | 維護 | 購買 |
| 09/23/2022 | 440.54% | Evercore ISI 集團 | $2 → 8 美元 | 升級 | 同步 → 跑贏大盤 |
| 08/15/2022 | 372.97% | HC Wainwright & Co. | 10 美元 → 7 美元 | 維護 | 購買 |
| 05/23/2022 | 575.68% | HC Wainwright & Co. | 37 美元 → 10 美元 | 維護 | 購買 |
| 05/20/2022 | 35.14% | 貝倫貝格 | → 2 美元 | 降級 | 買入 → 持有 |
| 05/17/2022 | 237.84% | 坎託·菲茨傑拉德 | 27 美元 → 5 美元 | 維護 | 超重 |
| 05/04/2022 | — | Cowen & Co. | 降級 | 跑贏大盤 → 市場表現 | |
| 05/04/2022 | 35.14% | Evercore ISI 集團 | 40 美元 → 2 美元 | 降級 | 跑贏大盤 → 在線 |
| 04/18/2022 | 2400% | HC Wainwright & Co. | 43 美元 → 37 美元 | 維護 | 購買 |
| 03/21/2022 | 2805.41% | HC Wainwright & Co. | 40 美元 → 43 美元 | 維護 | 購買 |
| 2021 年 1 月 10 日 | — | 奧本海默 | 降級 | 跑贏大盤 → 表現 | |
| 2021 年 1 月 22 日 | 2602.7% | HC Wainwright & Co. | 33 美元 → 40 美元 | 維護 | 購買 |
| 2020 年 12 月 16 日 | 3075.68% | 貝倫貝格 | → 47 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/23/2020 | 2129.73% | HC Wainwright & Co. | 28 美元 → 33 美元 | 維護 | 購買 |
| 09/29/2020 | 4629.73% | Evercore ISI 集團 | → 70 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 05/11/2020 | 1791.89% | HC Wainwright & Co. | 25 美元 → 28 美元 | 重申 | → 購買 |
| 03/17/2020 | 1318.92% | Stifel | 22 美元 → 21 美元 | 維護 | 購買 |
| 11/05/2019 | 2264.86% | HC Wainwright & Co. | 28 美元 → 35 美元 | 維護 | 購買 |
| 09/09/2019 | — | 詹尼蒙哥馬利斯科特 | 啓動覆蓋開啓 | → 購買 | |
| 09/04/2019 | 1791.89% | HC Wainwright & Co. | → 28 美元 | 假設 | → 購買 |
| 10/16/2018 | 508.11% | B of A 證券 | 19 美元 → 9 美元 | 降級 | 中性 → 跑贏大盤 |
What is the target price for Spero Therapeutics (SPRO)?
Spero Therapeutics（SPRO）的目標價格是多少？
The latest price target for Spero Therapeutics (NASDAQ: SPRO) was reported by HC Wainwright & Co. on July 20, 2023. The analyst firm set a price target for $6.00 expecting SPRO to rise to within 12 months (a possible 305.41% upside). 5 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年7月20日公佈了Spero Therapeutics（納斯達克股票代碼：SPRO）的最新目標股價。這家分析公司將目標股價定爲6.00美元，預計SPRO將在12個月內升至12個月內（可能上漲305.41％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Spero Therapeutics (SPRO)?
分析師對Spero Therapeutics（SPRO）的最新評級是多少？
The latest analyst rating for Spero Therapeutics (NASDAQ: SPRO) was provided by HC Wainwright & Co., and Spero Therapeutics reiterated their buy rating.
Spero Therapeutics（納斯達克股票代碼：SPRO）的最新分析師評級由HC Wainwright & Co. 提供，Spero Therapeutics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Spero Therapeutics (SPRO)?
Spero Therapeutics（SPRO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on July 20, 2023 so you should expect the next rating to be made available sometime around July 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Spero Therapeutics的高管和客戶交談，以及聽取財報電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Spero Therapeutics的最後一次評級是在2023年7月20日提交的，因此你應該預計下一個評級將在2024年7月20日左右公佈。
Is the Analyst Rating Spero Therapeutics (SPRO) correct?
分析師對 Spero Therapeutics (SPRO) 的評級正確嗎？
While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a reiterated with a price target of $0.00 to $6.00. The current price Spero Therapeutics (SPRO) is trading at is $1.48, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Spero Therapeutics（SPRO）評級得到了重申，目標股價爲0.00美元至6.00美元。Spero Therapeutics（SPRO）目前的交易價格爲1.48美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。